Eli Lilly’s Zepbound pricing shuffle leaves some patients fearing higher costs

Date:

August 28, 2024

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but some patients see the company’s changes as putting the medication further out of reach.

Source link

Auditor faults Pennsylvania agency over fees from Medicaid-funded prescriptions

Think You Can Retire? Seniors Who Have Had to Go Back to Work in Kamala's Economy Say 'Think Again'

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Eli Lilly’s Zepbound pricing shuffle leaves some patients fearing higher costs

Recent posts

Dogecoin soars as altcoins look to benefit from Trump presidency

Amazon hit with $5.9 million fine as California says it failed to disclose quotas to workers

What an August election-year rally for stocks could mean for Wall Street’s ‘Great Rotation’

UBS to put Credit Suisse Real Estate Fund International into liquidation

Hint of ‘very high’ consumer inflation expectations raises risks for Treasury market

Stocks usually see double-digit gains under U.S. presidents — with two exceptions since 1933

These maps show the oil and gas infrastructure in Francine’s path

Norfolk Southern got more efficient in Q2 despite derailment settlement, shareholder fight

Paramount to lay off staff, follows WBD in taking big charge on cable business

Tommy Bahama maker says shoppers are still ‘more cautious than originally anticipated,’ but cites this improvement

Kamala Harris pitches student-loan forgiveness to teachers union: ‘A future where no teacher has to struggle with the burden’

Boeing’s defense chief is leaving, company says

Nvidia’s bonds are a buy even as the stock sputters over growth concerns

Israel’s attack on Iran spares oil, nuclear facilities and probably markets too

Fed tends to look past hurricanes, although that is getting harder

Related articles

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Powell says Fed doesn’t need to hurry to cut interest rates

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Off-price retailers could thrive, BofA says, citing this bullish data point

Republicans clinch control of House, setting stage for quicker action on extending tax cuts

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Cava is riding a strong wave, but the stock’s quadrupling in 2024 has analysts wary

Wells Fargo touches all-time high as analyst hikes price target to new level

Company

Follow us